Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions


Answer 5
  1. ß-Blocker therapy should not be initiated in patients with severe class IV CHF. Recent data from the Copernicus trial revealed a significant decrease in mortality with use of carvedilol in patients with class IV heart failure. Subgroup analysis of a much smaller population from the MERIT trial showed mortality benefit from metoprolol tartrate in this patient group. Since ß-blockers have different receptor affinities, they cannot be considered interchangeable as a pharmacologic class for the treatment of CHF.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj